アブストラクト
| Title | 免疫チェックポイント阻害薬の有効性と安全性 |
|---|---|
| Subtitle | 今月のテーマ (総説) : 肝細胞癌における薬物治療の進歩 |
| Authors | 古瀬純司1) |
| Authors (kana) | |
| Organization | 1)杏林大学医学部腫瘍内科学 |
| Journal | 日本消化器病学会雑誌 |
| Volume | 118 |
| Number | 5 |
| Page | 400-406 |
| Year/Month | 2021 / 5 |
| Article | 報告 |
| Publisher | 日本消化器病学会 |
| Abstract | 要旨:切除不能肝細胞癌に対する免疫チェックポイント阻害薬(ICI)は, 抗PD-1抗体薬ニボルマブとペムブロリズマブの第III相試験がそれぞれ1次治療と2次治療で行われたが, 統計学的な有意差が得られなかった. 続いてICIベース併用療法の有効性が前臨床試験や早期臨床試験によって示唆され, いくつかの第III相試験が進められている. その中で, 抗PD-L1抗体薬アテゾリズマブ+抗VEGF抗体薬ベバシズマブの有効性が確認され, 2020年, 適応が承認された. 現在, 根治治療後の補助療法や肝動脈化学塞栓療法との併用でもICIの臨床試験が行われている. 一方, 免疫関連有害事象への適切な対応が求められる. |
| Practice | 臨床医学：内科系 |
| Keywords | 肝細胞癌, 薬物療法, 免疫チェックポイント阻害薬, 血管新生阻害薬, 免疫関連有害事象 |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) El-Khoueiry AB, Sangro B, Yau T, et al: Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389;2492-2502:2017
- 2) Crocenzi TS, El-Khoueiry AB, Yau TC, et al: Nivolumab (nivo) in sorafenib (sor)-naive and-experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study. J Clin Oncol 35(suppl); abstr4013:2017
- 3) Yau T, Park JW, Finn RS, et al: CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol 30(suppl 5);v874-v875:2019
- 4) Finn RS, Ryoo BY, Merle P, et al: Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol 38;193-202:2020
- 5) Morse MA, Sun W, Kim R. et al: The role of angiogenesis in hepatocellular carcinoma. Clin Cancer Res 25;912-920:2019
残りの11件を表示する
- 6) Kimura T, Kato Y, Ozawa Y, et al: Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepal-6 hepatocellular carcinoma model. Cancer Sci 109;3993-4002:2018
- 7) Lee MS, Ryoo BY, Hsu CH, et al: Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol 21;808-820:2020
- 8) Finn RS, Ikeda M, Zhu AX, et al: Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol 38;2960-2970:2020
- 9) Yau T, Kang YK, Kim TY, et al: Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 Randomized Clinical Trial. JAMA Oncol 6;e204564:2020
- 10) Kelly RK, Sangro B, Harris W, et al: Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab in combination with durvalumab for patients with advanced hepatocellular carcinoma. J Clin Oncol 38(suppl);abstr 4508:2020
- 11) Finn RS, Qin S, Ikeda M, et al: Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382;1894-1905:2020
- 12) Le DT, Uram JN, Wang H, et al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372;2509-2520:2015
- 13) Le DT, Durham JN, Smith KN, et al: Mismatch repair deficiency predicts rcsponse of solid tumors to PD-1 blockade, Science 357;409-413:2017
- 14) Schumacher TN, Schreiber RD: Neoantigens in cancer immunotherapy. Science 348;69-74:2015
- 15) Marabelle A, Le DT, Ascierto PA, et al: Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 38;1-10:2020
- 16) Brahmer JR, Lacchetti C, Schneider BJ, et al: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36;1714-1768:2018
